Castle Biosciences

The approvals allow the company to offer its PCR-based expression profile cancer risk tests in the state.

The company announced positive coverage decisions from Palmetto GBA, 14 BCBS plans, and Aetna.

Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.

The Medicare contractor is proposing to not cover Vectra DA, but to extend coverage for Prolaris, Xpresys, and DecisionDx-UM under specific circumstances.

The company's new $14 million facility refinances its original $6 million loan, and adds capital for new growth.

The first tranche of the targeted $20 million financing round will be used to accelerate adoption of the company's melanoma test.

The financing will go toward commercial and clinical activities to increase adoption of the company's DecisionDx-Melanoma test.

The study demonstrated that the company's DecisionDx-Melanoma assay better predicts the risk of metastasis in patients with localized disease than clinical staging alone.

Pages

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.